Aflac second-quarter total revenues increase 15.5% to $5.0 billion

NewsGuard 100/100 Score

Aflac Incorporated today reported its second quarter results.

Reflecting the benefit from a stronger yen/dollar exchange rate and lower realized investment losses, total revenues rose 15.5% to $5.0 billion in the second quarter of 2010, compared with $4.3 billion in the second quarter of 2009.  Net earnings were $581 million, or $1.23 per diluted share, compared with $314 million, or $.67 per share, a year ago.  

Net earnings in the second quarter of 2010 included after-tax realized investment losses of $58 million, or $.12 per diluted share, compared with realized investment losses of $249 million, or $.53 per share a year ago. Securities transactions produced realized investment gains of $8 million, or $.02 per diluted share, in the second quarter, which included a gain of $81 million from the exchange of two perpetual securities, a loss of $67 million from the company's sale of its Greek sovereign holdings and a loss of $6 million from various smaller securities transactions. In addition, the company realized a loss of $66 million, or $.14 per diluted share, from valuing foreign currency, interest rate and credit default swaps on certain variable interest entities that were required to be consolidated following adoption of Accounting Standards Codification (ASC) 810, effective January 1, 2010.  The bonds associated with these swaps were in an unrealized gain position at June 30, 2010, and changes in the fair value of the bonds are reflected in shareholders' equity.

Aflac believes that an analysis of operating earnings, a non-GAAP financial measure, is vitally important to an understanding of the company's underlying profitability drivers.  Aflac defines operating earnings as the profits derived from operations before realized investment gains and losses from securities transactions and the impact from ASC 810; the impact from ASC 815; and nonrecurring items. Management uses operating earnings to evaluate the financial performance of Aflac's insurance operations because realized gains and losses from securities transactions and the impact from ASC 810, the impact from ASC 815, and nonrecurring items tend to be driven by general economic conditions and events, and therefore may obscure the underlying fundamentals and trends in Aflac's insurance operations.

Furthermore, because a significant portion of Aflac's business is in Japan, where the functional currency is the Japanese yen, the company believes it is equally important to understand the impact on operating earnings from translating yen into dollars.  Aflac Japan's yen-denominated income statement is translated from yen into dollars using an average exchange rate for the reporting period, and the balance sheet is translated using the exchange rate at the end of the period.  However, except for a limited number of transactions, the company does not actually convert yen into dollars.  As a result, Aflac views foreign currency as a financial reporting issue and not as an economic event for the company or its shareholders.  Because changes in exchange rates distort the growth rates of operations, readers of Aflac's financial statements are also encouraged to evaluate financial performance excluding the impact of foreign currency translation.  The chart toward the end of this release presents a comparison of selected income statement items with and without foreign currency changes to illustrate the effect of currency.

Operating earnings in the second quarter were $639 million, compared with $562 million in the second quarter of 2009.  Operating earnings per diluted share rose 12.5% to $1.35 in the quarter, compared with $1.20 a year ago.  The stronger yen/dollar exchange rate increased operating earnings per diluted share by $.02 during the second quarter.  Excluding the impact from the stronger yen, operating earnings per share increased 10.8%.

Results for the first six months of 2010 also benefited from the stronger yen.  Total revenues were up 10.0% to $10.0 billion, compared with $9.1 billion in the first half of 2009.  Net earnings were $1.2 billion, or $2.58 per diluted share, compared with $882 million, or $1.89 per share, for the first six months of 2009.  Operating earnings for the first half of 2010 were $1.3 billion, or $2.76 per diluted share, compared with $1.1 billion, or $2.42 per share, in 2009.  Excluding the benefit of $.07 per share from the stronger yen, operating earnings per diluted share rose 11.2% for the first six months of 2010.

Total investments and cash at the end of June 2010 were $79.5 billion, compared with $74.0 billion at March 31, 2010.  The increase in total investments and cash resulted from improvement in the fair values of the company's investments since the end of the first quarter and the strengthening of the yen.

Shareholders' equity was $10.0 billion at June 30, 2010, compared with $9.0 billion at March 31, 2010.  Shareholders' equity at the end of the second quarter included a net unrealized gain on investment securities and derivatives of $136 million, compared with a net unrealized loss of $214 million at the end of March 2010.  Shareholders' equity per share was $21.31 at June 30, 2010, compared with $19.14 per share at March 31, 2010.  The annualized return on average shareholders' equity in the second quarter was 24.5%.  On an operating basis (excluding realized investment losses and the impact from ASC 815 on net earnings, and unrealized investment and derivative gains/losses in shareholders' equity), the annualized return on average shareholders' equity was 26.8% for the second quarter.

AFLAC JAPAN

Aflac Japan's total revenues in yen were up 3.2% in the second quarter of 2010. Premium income in yen rose 3.8%, and net investment income increased 3.0%.  Investment income growth in yen terms was suppressed by the stronger yen/dollar exchange rate because approximately 34% of Aflac Japan's second quarter investment income was dollar-denominated.  Reflecting the continued improvement in the benefit ratio, the pretax operating profit margin expanded from 19.7% to 21.1%.  As a result, pretax operating earnings in yen increased 10.8%.  For the first half of the year, premium income in yen increased 3.5%, and net investment income rose 2.7%.  Total revenues in yen were up 3.4%, and pretax operating earnings grew 13.7%.

The average yen/dollar exchange rate in the second quarter of 2010 was 92.05, or 6.0% stronger than the average rate of 97.53 in the second quarter of 2009.  For the first six months, the average exchange rate was 91.26, or 4.6% stronger than the rate of 95.44 a year ago.  Aflac Japan's growth rates in dollar terms for both the second quarter and first six months were magnified as a result of the stronger average yen/dollar exchange rates.

Reflecting the stronger yen, premium income in dollars rose 9.8% to $3.2 billion in the second quarter.  Net investment income was up 9.0% to $593 million.  Total revenues increased 9.2% to $3.8 billion.  Pretax operating earnings rose 17.4% to $798 million.  For the first six months, premium income was $6.4 billion, or 8.1% higher than a year ago.  Net investment income rose 7.4% to $1.2 billion.  Total revenues were up 8.0% to $7.6 billion.  Pretax operating earnings were $1.6 billion, or 19.0% higher than a year ago.

Aflac Japan again produced better-than-expected sales results.  Total new annualized premium sales rose 12.6% to 33.9 billion yen in the second quarter of 2010.  In dollar terms, total new annualized premium sales were $368 million.  For the first six months of the year, total new annualized premium sales were up 11.4% to 64.1 billion yen, or $702 million. Sales of ordinary life insurance were very strong in the second quarter and primarily reflected the popularity of the child endowment product.  Ordinary life sales rose 42.0% in yen and accounted for approximately 38% of total new sales in the second quarter.  The strong sales performance in the quarter was also driven by contributions from EVER, Aflac Japan's market-leading medical product. Medical sales rose 23.5% in the second quarter of 2010, compared with a year ago. Bank channels sales continued a strong trend of growth.  Bank channel sales were a record 3.9 billion yen in the second quarter, increasing 26.0% over the first quarter of 2010 and 177.7% over the second quarter of 2009.

AFLAC U.S.

Aflac U.S. total revenues rose 5.1% to $1.3 billion in the second quarter. Premium income increased 4.9% to $1.1 billion, and net investment income was up 6.1% to $135 million. Pretax operating earnings were $227 million, an increase of 15.0%.  For the first six months, total revenues were up 4.4% to $2.6 billion and premium income rose 4.2% to $2.3 billion.  Net investment income increased 5.9% to $267 million. Pretax operating earnings were $471 million, or 17.3% higher than a year ago.

Aflac U.S. sales continued to be impacted by weak economic conditions in the United States.  In the second quarter, total new sales declined 2.4% to $333 million. Total new sales included Aflac Group Insurance sales of $10 million in the second quarter of 2010. For the first half of the year, total new sales were $649 million, or 6.3% below a year ago.  As expected, recruitment of new sales associates was down in the quarter, compared with a year ago, but fairly consistent with first quarter 2010 recruitment levels.

DIVIDEND

The board of directors declared the third quarter cash dividend.  The third quarter dividend of $.28 per share is payable on September 1, 2010, to shareholders of record at the close of business on August 18, 2010.

OUTLOOK

Commenting on the company's second quarter results, Chairman and Chief Executive Officer Daniel P. Amos stated: "We are pleased with Aflac's financial performance in the second quarter of 2010 and believe we have made significant progress toward our annual objectives for operating earnings growth and capital strength.  Aflac Japan's operations have remained strong while producing significant sales growth.  As a result, we believe we are well-positioned to achieve our full-year sales target in Aflac Japan, our largest segment.  Sales in the United States continue to be challenged by the extended weak economic environment, however we are encouraged by the recent improvement in the productivity of our veteran sales associates.  Although we expect third quarter sales to be lower than a year ago, we remain hopeful we will see U.S. sales turn in the second half of the year.

"Despite ongoing volatility in capital markets, we are also pleased with the quality of our balance sheet and our capital position. Along those lines, we took advantage of opportunities to enhance our portfolio during the second quarter by selling and exchanging certain investments.  In addition, total realized investment losses in the second quarter were significantly lower than a year ago.  We remain especially pleased with the continued strength of our capital position.  Based on preliminary statutory numbers, we estimate our risk-based capital ratio exceeded 560% at the end of June, compared with 539% at the end of the first quarter.

"With half of the year complete, we believe we are in a very good position to meet our earnings objectives and extend our record of growth.  Our objective for 2010 is to increase operating earnings per diluted share by 9% to 12%, excluding the impact of the yen.  Within that range, we expect operating earnings to increase approximately 10% for the full year to $5.34 per diluted share before the impact of foreign currency. If the yen averages 90 to the dollar for the remainder of the year, we would expect full-year reported earnings to be about $5.44 per diluted share. Using that same exchange rate assumption, we expect third quarter operating earnings of $1.35 to $1.38 per diluted share. Our objective for 2011 of increasing operating earnings by 8% to 12% before the impact of foreign currency also remains unchanged."

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.